Results 21 to 30 of about 1,401 (50)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Biomarker Research, 2019
Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and ...
Xiaoyan Liu, Yuping Gong
doaj   +1 more source

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism

Frontiers in Endocrinology, 2020
Aim: Isocitrate dehydrogenase 1 (IDH1) is key enzyme involved in cellular metabolism and DNA repair. Mutations in IDH1 occur in up to 25% of cholangiocarcinomas.
Li Su, Xinglong Zhang, Lei Zheng, Miaomiao Wang, Zhifa Zhu, Ping Li   +5 more
doaj   +1 more source

Ventajas de la secuenciación de próxima generación sobre la hibridación fluorescente in situ para detectar la codeleción 1p/19q en oligodendrogliomas

Medicina U.P.B., 2023
El perfil molecular de los gliomas permite garantizar la precisión del diagnóstico, informar el pronóstico e identificar opciones de tratamiento.
León Darío Ortiz, David Andrés Galvis, Ronald Guillermo Peláez, Carlos Jaime Yepes, Piedad Matilde Agudelo   +4 more
doaj   +1 more source

Mutasi Isocitrate Dehydrogenase 1 dan 2 pada Glioma

JBN (Jurnal Bedah Nasional), 2020
Klasifikasi tumor sistem saraf pusat WHO terakhir didasarkan atas histogenesis tumor dan karakteristik molekuler genetik. Perubahan klasifikasi yang paling signifikan terjadi pada tumor glioma difus yang paling signifikan, yaitu katagori tumor secara ...
Ni Putu Sriwidyani
doaj   +1 more source

Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients

Medeniyet Medical Journal, 2023
Objective: Neuroblastoma is one of the common tumors of childhood. The demonstration of new factors such as isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations will be important in the diagnosis and treatment.
Emre LEVENTOGLU, Gurses SAHIN, Sule YESIL, Ceyhun BOZKURT, Nazmiye YUKSEK, Ali FETTAH, Sule TOPRAK, Burcak KURUCU BILGIN, Emre CAPKINOGLU, Nilgun EROGLU, Sibel AKPINAR TEKGUNDUZ, Ayse Ulya ERTEM   +11 more
doaj   +1 more source

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review

Current Issues in Molecular Biology, 2022
Both IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2) mutations play a vital role in the development of gliomas through disruption of normal cellular metabolic processes.
Alexander Yuile, Laveniya Satgunaseelan, Joe Wei, Marina Kastelan, Michael F. Back, Maggie Lee, Heng Wei, Michael E. Buckland, Adrian Lee, Helen R. Wheeler   +9 more
doaj   +1 more source

Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article

مجلة كلية الطب
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram, Fadhel M. Lafta, Bassam F. Matti   +2 more
doaj   +1 more source

Adjunctive perampanel for glioma-associated epilepsy

Epilepsy and Behavior Case Reports, 2018
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy.
Anastasie M. Dunn-Pirio, Sarah Woodring, Eric Lipp, James E. Herndon, II, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, Katherine B. Peters   +9 more
doaj   +1 more source

Salicylanilide Diethyl Phosphates as Potential Inhibitors of Some Mycobacterial Enzymes

The Scientific World Journal, 2014
Antimycobacterially active salicylanilide diethyl phosphates were evaluated to identify their potential drug target(s) for the inhibition of several mycobacterial enzymes, including isocitrate lyase, L-alanine dehydrogenase (MtAlaDH), lysine ε ...
Martin Krátký, Eva Novotná, Shalini Saxena, Perumal Yogeeswari, Dharmarajan Sriram, Markéta Švarcová, Jarmila Vinšová   +6 more
doaj   +1 more source

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Frontiers in Oncology, 2019
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub, Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Karen Tang, Aram S. Modrek, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis   +13 more
doaj   +1 more source